Maybe, you know, we took care to make sure that our distribution of men and women was roughly even across both of these groups, but maybe by, through that random sampling, we got a disproportionate number of young people in the treatment group, and maybe young people responded better to taking a pill. Maybe it changes their behaviors in other ways, or maybe older people, when they take a pill, they decide to eat worse because they say, oh, this pill's gonna solve all my problems. And so you could have these other lurking variables, like age, or where in the country they live, or other types of things, that just by the random process, you might have things get uneven in one way or another. Now, one technique to help control for this a little bit, and I shouldn't use the word control too much, another technique to help mitigate this is something called matched pairs design. Matched, matched pairs, pairs design of an experiment, and it's essentially, instead of going through all of this trouble saying, oh boy, maybe we do block design, all this random sampling, instead, you randomly put people first into either the control or the treatment group, and then we do another round, you measure, and then you do another round where you switch, where the people who are in the treatment go into the control, and the people who are in the control go into the treatment. So we could even extend from what we have here, we could imagine a world where the first three months, we have the 50 people in this treatment group, we have another 50 people in this control group that are taking the placebo, we see what happens to the A1Cs, and then we switch, where this group over here, then, and they don't know, they don't know, first of all, ideally, it's a blind experiment, so they don't even know they were in the treatment groups, and hopefully the pills look identical, so now, that same group, for the next three months, is now going to be the control group, and so they got the medicine for the first three months, and we saw what happens to their A1C, and now they're gonna get the placebo, they're going to get the placebo for the second three months, and then we are going to see what happens to their A1C, and likewise, the other group is going to be switched around. The thing that, the folks that used to be getting the placebo could now get, could now get the treatment.